ALLUVI: A DEEP ANALYSIS INTO THE DRUG'S POSSIBILITY

Alluvi, previously known as LY3414901, represents a significant advancement in weight management. This dual -action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist demonstrates remarkable efficacy in early clinical data, with impressive redu